{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Peng T"],"funding":["Young Talent Development Plan of Changzhou Health Commission","Changzhou No.2 People's Hospital Young Scientists Foundation"],"pagination":["1373"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7809464"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["The correlation between G388R or V10I polymorphisms of fibroblast growth factor receptor (FGFR) 4 gene and the risk of carcinoma has been investigated previously, but the results are contradictory. Odds ratios (ORs) with 95% confidence intervals (95%CIs), in silico tools, and immunohistochemical staining (IHS) were adopted to assess the association. In total, 13,793 cancer patients and 16,179 controls were evaluated in our pooled analysis. Summarization of all the studies showed that G388R polymorphism is associated with elevated susceptibility to cancer under homozygous comparison (OR = 1.21, 95%CI = 1.03-1.43, P = 0.020) and a recessive genetic model (OR = 1.21, 95%CI = 1.04-1.41, P = 0.012). In the stratification analysis by cancer type and ethnicity, similar findings were indicated for"],"journal":["Scientific reports"],"pubmed_title":["Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer."],"pmcid":["PMC7809464"],"funding_grant_id":["No. CZQM2020065","2019K008"],"pubmed_authors":["Lv Z","Shi L","Peng T","Zuo L","Sun Y","Zhou X","Wu H","Zhang W","Mi Y","Su Q","Zhang Z","Zhang LF","Yuan W"],"additional_accession":[]},"is_claimable":false,"name":"Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer.","description":"The correlation between G388R or V10I polymorphisms of fibroblast growth factor receptor (FGFR) 4 gene and the risk of carcinoma has been investigated previously, but the results are contradictory. Odds ratios (ORs) with 95% confidence intervals (95%CIs), in silico tools, and immunohistochemical staining (IHS) were adopted to assess the association. In total, 13,793 cancer patients and 16,179 controls were evaluated in our pooled analysis. Summarization of all the studies showed that G388R polymorphism is associated with elevated susceptibility to cancer under homozygous comparison (OR = 1.21, 95%CI = 1.03-1.43, P = 0.020) and a recessive genetic model (OR = 1.21, 95%CI = 1.04-1.41, P = 0.012). In the stratification analysis by cancer type and ethnicity, similar findings were indicated for","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan","modification":"2026-04-18T05:07:28.464Z","creation":"2021-02-21T01:14:20Z"},"accession":"S-EPMC7809464","cross_references":{"pubmed":["33446698"],"doi":["10.1038/s41598-020-80146-y"]}}